Peptonic Medical's Rights Issue Yields 62.1% Subscription
Peptonic Medical AB reports a 62.1% subscription rate in its recent Rights Issue, raising SEK 16.5 million.
Sammanfattning
Peptonic Medical AB's Rights Issue concluded with a 62.1% subscription rate, raising approximately SEK 16.5 million. The company aims to use these funds to further its growth strategy.
Peptonic Medical AB, a Swedish medtech company, has successfully concluded its Rights Issue, achieving a subscription rate of 62.1%. This outcome translates to 71,562,122 units subscribed, bringing in approximately SEK 16.5 million before issue costs. The Rights Issue attracted interest both from existing shareholders and new investors, with 44.8% of subscriptions made through unit rights and 9.8% without.
The company offered each unit at a subscription price of SEK 0.0046 per share, comprising 50 newly issued shares per unit. Notably, top-down underwriters contributed to 7.5% of the total subscriptions, underscoring confidence in Peptonic's strategic direction.
Peptonic's share capital has increased significantly, with an addition of 3,578,106,100 shares, elevating the total share count to 9,337,409,114. This capital boost is poised to support Peptonic's ambitious growth strategy, focusing on expanding its geographic footprint in the U.S. and Europe, and enhancing its product portfolio.
The funds raised will be strategically deployed to bolster Peptonic's market position, particularly through its brands VagiVital and Vernivia, which offer innovative solutions for women's intimate health. The company's focus on clinically proven self-care products aligns well with current health trends, potentially driving future growth.
Given the successful outcome of the Rights Issue and Peptonic's solid strategic plans, the recommendation for investors is to hold their positions. The company is on a promising growth trajectory, and maintaining investments could yield positive returns as Peptonic continues to execute its expansion and product development strategies.
Källa
Sammanfattning
The subscription period for Peptonic Medical AB's Rights Issue ended on February 24, 2025, resulting in 71,562,122 units being subscribed, representing about 62.1% of the total offering. Of these, 51,625,491 units were subscribed using unit rights, 11,240,979 units without unit rights, and 8,695,652 units by top-down underwriters. Each unit comprises 50 newly issued shares, totaling 3,578,106,100 new shares. The Rights Issue will raise approximately SEK 16.5 million before costs, with SEK 4.5 million paid through offset. The allocation for units subscribed without unit rights followed the guidelines in the company's information document. The company's total shares increased from 5,759,303,014 to 9,337,409,114, and share capital rose to approximately SEK 42,952,081.92. Trading with paid subscribed units (BTU) will continue on the Spotlight Stock Market until the conversion to shares after registration with the Swedish Companies Registration Office in week 12 of 2025. Underwriters will receive compensation, with a choice between cash or units, and must notify Mangold Fondkommission AB by March 7, 2025. Mangold Fondkommission AB and Eversheds Sutherland Advokatbyrå AB are advising Peptonic in this process. Peptonic Medical AB is a Swedish medtech company focused on women's intimate health, aiming for growth through geographic expansion and product development. The information disclosed is in compliance with the EU Market Abuse Regulation and is not an offer or solicitation for securities in any jurisdiction.
